Description: H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.
Home Page: www.lundbeck.com
Ottiliavej 9
Valby,
2500
Denmark
Phone:
45 36 30 13 11
Officers
Name | Title |
---|---|
Mr. Charl van Zyl | President & CEO |
Mr. Joerg Hornstein | CFO & Executive VP of Corporate Functions |
Mr. Lars Bang | Executive Vice President of Product Development & Supply |
Dr. Per Johan Luthman Ph.D. | Executive Vice President of Research & Development |
Dr. Tarek Samad Ph.D. | Senior VP & Head of Research |
Mr. Palle Holm Olesen | Chief Specialist & VP of Investor Relations |
Ms. Tine Ostergaard Hansen | Senior Vice President of Corporate Communications & Public Affairs |
Ms. Dianne Holto | Executive Vice President of People & Culture |
Mr. Ole Chrintz | Senior Vice President of International Markets |
Dr. Rupert Sandbrink M.D., Ph.D. | Senior VP & Head of Clinical Development |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 13.4953 |
---|---|
Trailing PE: | 16.0526 |
Price-to-Book MRQ: | 1.802 |
Price-to-Sales TTM: | 2.0026 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 5681 |